Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
about
Two ghrelin receptor agonists for adults with malnutrition: a systematic review and meta-analysisTherapeutic Potential of Targeting the Ghrelin Pathway.Oral Treatment with the Ghrelin Receptor Agonist HM01 Attenuates Cachexia in Mice Bearing Colon-26 (C26) TumorsModified glasgow prognostic score in patients with small-cell lung cancerAnamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.The role of adipose tissue in cancer-associated cachexia.Oncology Update: Anamorelin.Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.An analysis of the types of recently published research in the field of cachexia.Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy.Managing an Older Adult with Cancer: Considerations for Radiation Oncologists.Cancer cachexia: Are we ready to take a step forward?Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs.Modulating Metabolism to Improve Cancer-Induced Muscle Wasting.Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia.
P2860
Q28079897-B3F077F0-6200-4488-B03E-B72C3C02B57BQ33624632-D78C18D4-D395-43D1-9ABA-1F62ABF7322BQ33755034-560898AB-CEDE-4B6B-9235-DE4C43C050DBQ33857754-2EFBE4AE-E3E4-48D9-972E-FE48D4369799Q38636513-801442F8-F705-4D21-9F13-3BAAA1B1C669Q38670238-6ACFDCBE-73F8-4A1E-981A-134B0412C45FQ38772058-9536E3A5-E06B-48BF-935E-D626FB41F0F2Q39033683-37DD20E5-E762-4ED6-969A-F3C9C9CF9B39Q41511150-DCCDB7C9-E14A-4F1E-904E-F74ADE905E8AQ47137154-42B3D94C-DBE7-4214-8360-13014BE93309Q47568983-C0FC1954-5BD4-4FE8-AE22-9F6BA6B99C94Q47690783-7CAE66FC-ACAA-49D8-B015-CF3B38E20B66Q47801764-C90B745F-D5E4-4EAD-AF39-4D31C0369250Q48128980-E83D9ABA-17ED-45B4-B71D-C857019486B5Q48181105-6DBEFA81-03FF-4E9E-BA20-EE3D204DB3C8Q50301613-83688D20-9AC6-486A-8D53-C13401C94D9EQ55301138-85C95C24-0B86-4AF5-9B82-1463B1DE1323Q55646811-FAF1D084-055B-4F52-B63A-2B6321CDC2E4
P2860
Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anamorelin (ONO-7643) in Japan ...... of a randomized phase 2 trial.
@en
Anamorelin
@nl
type
label
Anamorelin (ONO-7643) in Japan ...... of a randomized phase 2 trial.
@en
Anamorelin
@nl
prefLabel
Anamorelin (ONO-7643) in Japan ...... of a randomized phase 2 trial.
@en
Anamorelin
@nl
P2093
P2860
P1476
Anamorelin (ONO-7643) in Japan ...... of a randomized phase 2 trial.
@en
P2093
Akira Koyama
Hiroshi Kagamu
Hiroshi Saito
Keisuke Aoe
Kenji Eguchi
Koichi Takayama
Kozo Yoshimori
Naoyuki Komura
Nobuyuki Katakami
Shinji Atagi
P2860
P2888
P304
P356
10.1007/S00520-016-3144-Z
P577
2016-03-23T00:00:00Z